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ABSTRACT 
The Role of Left Atrial Chamber Size 
as Assessed by Echocardiography in Determining 
Thromboembolic Complications of Atrial Fibrillation 
by 
Cynthia Ann Hall 
1986 
To examine the usefulness of left atrial chamber size in 
predicting patients at risk for thromboembolic complications 
of atrial fibrillation without mitral stenosis, this study 
examined 176 patients having atrial fibrillation without 
mitral stenosis. All patients had left atrial chamber size 
measured by 2-D and M-Mode study. Clinical charts were 
reviewed for evidence of systemic embolization (central 
nervous system, mesenteric and peripheral). At the end of 
the study period, 25/116 (22%) patients with left atrial 
chamber size greater than or equal to 4.0cm as compared to 
4/60(7%) patients with left atrial chamber size less than 
4.0cm experienced a systemic embolism (p=.01). Therefore 
patients with atrial fibrillation without mitral stenosis 
and left atrial chamber size greater than or equal to 4.0cm 

have a 3 time greater embolic frequency than patients 
with left atrial chamber size less than 4.0cm. Twenty-one of 
ninety-eight (21%) of patients with underlying organic heart 
disease embolized as compared to 8/78(10%) patients without 
heart disease who embolized (p < .05). Patients with chronic 
atrial fibrillation were more likely to embolize than those 
with paroxysmal atrial fibrillation. The risk of 
embolization was not confined to any discrete time period 
after the onset of atrial fibrillation. 

TABLE OF CONTENTS 
INTRODUCTION 1 
CLINICAL MATERIALS AND METHODS 3 
RESULTS 9 





In the 1950's systemic embolization was shown to be a serious 
complication of atrial fibrillation when associated with mitral stenosis 
(1). Other researchers have since confirmed this finding (2,3,4). 
Because these thromboembolic events may have devastating consequences 
(5) efforts to prevent their occurrence are justified. Although other 
clinical entities associated with atrial fibrillation have been reported 
to increase the risk of embolization (2,3,4), the only widely accepted 
indication for anticoagulation in patients with atrial fibrillation is 
the presence of mitral stenosis. Unanswered questions regarding the 
efficacy, duration and risk of anticoagulation therapy have resulted in 
patients being untreated unless, the risk of embolization outweighed the 
risk of anticoagulation therapy. The incidence of spontaneous bleeding 
ranges from less than 1% to almost 10% on heparin therapy and 
complicates at least 5% of all courses of wafarin therapy, despite close 
regulation (10). Therefore, in this paper, patients with atrial 
fibrillation without mitral stenosis were reviewed to assess their 
overall risk of embolization and to identify any factors that could 
increase or decrease their risk. In particular, all patients underwent 
an echocardiogram to assess the influence of left atrial chamber size on 
embolic risk. This study showed that patients with atrial fibrillation 
without mitral stenosis and left atrial chamber size greater than or 
equal to 4.0cm were at three times greater risk for embolization than 

those with left atrial size less than 4.0cm. Additionally, the presence 
of underlying heart disease, chronic atrial fibrillation and increased 
age significantly increased the embolic risk in the study population. 

Clinical Materials and Methods 
Patients with atrial fibrillation who underwent an 
echocardiographic examination from January 1980 to December 1983 were 
identified. The period of time from the individual patient's 
echocardiogram to December 1985 was considered the total period of this 
study. A diagnosis of atrial fibrillation was accepted only if 
electrocardiographic evidence (6) or a physician's interpretation of an 
electrocardiogram could be obtained from the patient charts. Patients 
with a clinical history of mitral stenosis were excluded as were 
patients with echocardiographic evidence of mitral stenosis. The 
clinical, surgical, pathological and laboratory records were reviewed 
for the following information: age, sex, duration of atrial 
fibrillation, duration of clinical follow-up after onset of atrial 
fibrillation, echocardiographic determination of left atrial chamber 
size (11), evidence of valvular disease (aortic stenosis, aortic 
insufficiency, mitral regurgitation) (11), presence of coronary heart 
disease, congestive heart failure, cardiomyopathy, diabetes mellitus, 
hyperthyroidism, history of anticoagulation with wafarin, heparin, or 
antiplatelet agents (Persantine and/or aspirin), history of tobacco or 
alcohol use during period of study. In addition, charts were reviewed 
for evidence of systemic arterial embolic events. (See the example of 
the 3 page data collection form used for each patient, Fig. 4). In 
addition left atrial chamber size was determined by echocardiography in 
each patient. Of the 296 cases compiled, an attempt to establish 
clinical follow-up with each patient was made. The follow-up consisted 
of a form letter mailed to the patient's last known address followed by 

a phone call to determine if a systemic embolism had occurred. The 
letter informed the patient of the study and alerted the patient that a 
follow-up phone call should be expected. During the phone conversation, 
the patient was asked about the use of anticoagulants, antiplatelet 
agents, additional hospitalizations since the time of echocardiogram and 
presence of symptoms consistent with an arterial embolic event. (See the 
example of the one page patient letter and one page questionnaire, Fig. 
2 and Fig. 3, respectively). A total of 120 patients were excluded from 





No follow-up obtainable because 
of death from unknown causes, 
patient unavailable, or unwilling 
to provide information. 
Simultaneous presentation of an 
arterial embolic event and atrial 
fibrillation 
Had prosthetic valve replacements 
prior to or during study. 
Had peri-operative embolic event 
during cardiac surgery and atrial 
fibrillation could not be 
documented prior to surgery. 
TOTAL 120 patients excluded 

The final number of confirmed cases of patients having atrial 
fibrillation without mitral stenosis with adequate follow-up reviewed in 
this study was 176. 
Onset of Atrial Fibrillation: 
The onset of atrial fibrillation was defined as the first 
electrocardiographic evidence of atrial fibrillation present in the 
patient chart or first documentation of atrial fibrillation by an 
attending physician in the medical records. Patients found to be in 
atrial fibrillation for the first time when hospitalized for an embolic 
event were excluded because it could not be determined whether atrial 
fibrillation preceeded the embolic event. 
Chronic vs Paroxsysmal Atrial Fibrillation: 
A separation between chronic and paroxysmal atrial fibrillation was 
made in this study. Paroxysmal atrial fibrillation was defined as 
patients whose medical records showed at least one spontaneous episode 
of normal sinus rhythm after onset of atrial fibrillation during the 
length of this study. Chronic atrial fibrillation was defined as 
patients with no documentation of spontaneous normal sinus rhythm after 
the onset of atrial fibrillation with at least 2 electrocardiograms more 
than one month apart. Undetermined type of atrial fibrillation was 
defined as patients with only 1 electrocardiogram in their medical 
records or less than one month between two consecutive 
electrocardiograms without spontaneous normal sinus rhythm. 
■ 
6. 
Definition of Arterial Embolic Event: 
Cases were reviewed for presentations of clinical emboli which were 
consistent with systemic arterial embolization. Embolic events were 
subdivided into 3 categories: central nervous system, mesenteric and 
peripheral events. In addition, embolic events were categorized 
according to correlation of clinical findings with laboratory findings. 
The arterial embolic event was considered to be definite if CT scan, 
angiographic or pathologic confirmation was available. A probable 
arterial embolic event lacked CT scan, angiographic and pathologic 
confirmation but clearly demonstrated physical neurologic deficits 
consistent with a cerebral vascular accident. A possible arterial 
embolic event was defined as a transient ischemic attack in the absence 
of carotid artery disease. 
a. Cerebral vascular accident based on clinical diagnosis 
with CT scan confirmation = Definite. 
b. Cerebral vascular accident based on clinical diagnosis 
without CT scan confirmation = Probable. 
c. Transient ischemic attack in the absence of carotid artery 
disease defined by absence of carotid bruits on physical 
examination = Possible. 
d. Onset of painful/numb extremity and/or loss of pulse with 
or without angiographic evidence of embolization resulting 
in embolectomy = Definite. 
e. Clinical findings of mesenteric ischemia or infarction with 
angiographic confirmation of embolization; liver, splenic 
or renal infarction documented by liver/spleen scan or 
renal angiography = Definite (27). 
■ 
7. 
Embolic events occurring before the echocardiogram were not included 
unless the patient experience a second event after the echocardiogram. 
Pulmonary embolisms were not included in this study. 
Echocardiographic Evaluation: 
Echocardiographic examinations were performed in a routine fashion 
with 2-D and M-Mode studies obtained in each patient. Left atrial 
chamber size was determined from the M-Mode study on each patient. 
Definition of Cardiac Disease: 
Non-Mitral Stenosis Valvular Disease: 
In this study we excluded patients with clinical evidence of mitral 
stenosis. Patients with the following valvular lesions identified by 
clinical assessment including echocardiogram were included: aortic 
stenosis, aortic insufficiency and mitral regurgitation. 
Coronary Heart Disease: 
Patients with a clinical history of ischemic cardiomyopathy, angina 
and/or myocardial infarction confirmed by electrocardiographic findings 
were included in this grouping. One patient had a left ventricular 
aneurysm detected by echocardiogaphy. 
Other Heart Disease: 
This group included patients with nonischemic cardiomyopathy with 
ejection fraction <45%, hypertrophic cardiomyopathy, congenital heart 
disease, mitral valve prolapse, Sick-Sinus Syndrome and 
Wolff-Parkinson-White Syndrome. 
No Cardiac Disease: 
Fhtients without any of the above mentioned cardiac abnormalities 
were included in this group. 
' 
8. 
Underlying Clinical Conditions: 
Patient charts were screened for presence of the following clinical 
conditions: angina, myocardial infarction, hypertension, 
hyperthyroidism, congestive heart failure and diabetes mellitus. A 
clinical history, laboratory values and/or x-ray studies were used to 
establish the presence of these clinical processes. 
History of Anticoagulation Therapy : 
Patients were considered to be anticoagulated if they were on an 
anticoagulant for greater than one month with therapeutic prothrombin 
times (1.5 times the control). In 4 patients the prothrombin times were 
not available but the patient stated that they were being followed by a 
physician and were told that their dose of anticoagulant was adequate. 
Statistical Methods of Analysis: 
The two-tailed test of significance and the nonparametric chi-square 





The overall frequency of systemic arterial embolic events in 
patients having atrial fibrillation without mitral stenosis was 29/176 
(17%). (See TABLE 1). Of the 29 arterial embolic events, 12/29 (41%) 
were definite, 14/29 (48%) probable and 3/29 ( 10%) were possible 
embolic events according to the criteria of CT scan confirmation, 
pathologic confirmation or embolectomy outlined in the methods. Of the 
total number of systemic arterial embolic events 24/29 (83%) involved 
the brain, 4/29 (14%) were peripheral and 1/29 (3%) was a mesenteric 
ischemic event. 
The study population was divided into 4 groups to assess the 
frequency of embolic events according to type and extent of underlying 
heart disease: valvular disease (excluding mitral stenosis), coronary 
heart disease (ischemic cardiomyopathy, angina and/or myocardial 
infarction), other heart disease (hypertrophic cardiomyopathy, 
nonischemic cardiomyopathy, congenital heart disease, mitral valve 
prolapse, Sick-Sinus Syndrome and Wolff-Parkinson-White Syndrome), and 
combined heart diseases. (See TABLE 2). In patients with only valvular 
heart disease 2/10 (20%) embolized, only coronary heart disease 10/65 
(15%) embolized, only "other” heart disease 2/10 (20%) embolized and 
with combined heart diseases 7/13 (54%) embolized. There was no 
significant difference between the embolic frequency of patients with 
only valvular heart disease, coronary heart disease or "other" heart 
disease. However, the presence or absence of any of the defined heart 
diseases was found to have a significant impact on embolic frequency. 

10. 
Twenty-one of ninety-eight (21%) patients with underlying heart disease 
embolized as compared to 8/78 (10%) of those without heart disease 
(P <.05). 
Duration of Atrial Fibrillation: 
The mean length of time from echo to embolic event was 7 months (0 
months - 45 months). The patients without emboli were followed for a 
mean of 35 months (0 days-71 months) from the time of echocardiography. 
The mean duration of atrial fibrillation from onset to the end of 
follow-up was 28 months (2 days-108 months) and 45 months (1 week - 228 
months) in the embolic and nonembolic groups, respectively. Of the 29 
patients with embolic events, 4 (14%) had the event within 1 week of the 
onset of atrial fibrillation, 4 (14%) from 2-4 weeks after the onset of 
atrial fibrillation, 1 (3%) from 2-6 months, 10 (35%) from 7-24 months 
and 10 (35%) from 3-9 years after the onset of atrial fibrillation. (See 
Figure 5). 
Chronic vs Paroxysmal Atrial Fibrillation: 
The type of atrial fibrillation as defined in the methods section 
proved to be an important influence on the frequency of embolic events. 
Twelve of forty-one (29%) patients with chronic atrial fibrillation 
embolized as compared to 13/104 (13%) of patients with paroxysmal atrial 
fibrillation. The difference between the frequencies was significant 
with P <.02. 

Underlying Clinical Conditions: 
The frequency of embolic events was similar in males and females. 
The mean age of the embolic group was 75 years _+ 8.38 years as compared 
to the mean age of the nonembolic group which was 70 years +_ 13.29 years 
(P=.0346). Four underlying clinical conditions were examined for their 
possible influence on the frequency of embolic events. Twelve of 
seventy-three (16%) patients with congestive heart failure (CHF) 
embolized compared to 17/103 (17%) patients without congestive heart 
failure (P=NS). Eighteen of twenty-four (21%) patients with 
hypertension (HTN) embolized compared to 11/92 (.12%) patients without 
hypertension (P=NS). Eight of thirty-one (26%) patients with diabetes 
mellitus embolized versus 21/145 (15%) of patients without diabetes 
mellitus (P=NS). Four of seventeen (24%) patients with hyperthyroidism 
embolized versus 25/159 (16%) of patients without hyperthyroidism (P=NS). 
Left Atrial Chamber Size: 
The left atrial chamber sizes of the study population were divided 
into 2 groups: chamber size greater than or equal to 4.0cm and less 
than 4.0cm. A left atrial chamber size of 4.0cm or greater was chosen 
to separate this population for analysis because 4.0cm exceeds the upper 
limits of normal. Left atrial chamber size of greater than or equal to 
4.0cm proved to be a very significant risk factor for embolization. 
Twenty-five of one-hundred and sixteen (22%) patients with left atrial 
chamber size greater than or equal to 4.0cm embolized compared to 4/60 
(7%) patients with left atrial chamber size less than 4.0cm (P=.01). 
Thus, patients with left atrial chamber size greater than or equal to 
4.0cm had 3 times the risk of embolization when compared to patients 
with left atrial chamber size less than 4.0cm. The mean left atrial 

chamber size of the embolic group was 4.40cm _+ .54cm. The mean left 
atrial chamber size of the nonembolic group was 4.14cm +_ 1.03cm (P=NS). 
(See Figure 1). 
Anticoagulation Status: 
During the follow-up process it was determined that five of one 
hundred and seventy-six (3%) patients were chronically anticoagulated 
for more than 2 years. In none of these patients did an embolic event 
occur. Among the anticoagulated patients, the left atrial chamber size 
did not differ from the remaining nonembolic patients. Twenty-seven of 
twenty-nine (93%) patients were anticoagulated or treated with 
antiplatelet agents after the embolic event occurred. In this study 
patients were not analyzed for frequency of recurrent embolic events. 
' 
DISCUSSION 
Atrial fibrillation is an idiopathic entity as well as a 
complication of a variety of underlying cardiac diseases. Atrial 
fibrillation is seen in cardiac disease states such as Sick-Sinus 
Syndrome, Wolff-Parkinson-White Syndrome, pericarditis, rheumatic heart 
disease, coronary heart disease, mitral regurgitation, idiopathic 
dilated cardiomyopathy hypertrophic and infiltrative cardiomyopathies. 
In addition, atrial fibrillation is often seen in isolation with no 
known cause. 
Unfortunately, atrial fibrillation has been associated with 
systemic embolization. Therefore, a variety of investigators have 
attempted to identify different clinical entities which increase a 
patient's risk of embolization when associated with atrial 
fibrillation. Thusfar, the literature has identified the following 
clinical entities: mitral stenosis/rheumatic heart disease, ischemic 
heart disease, hypertrophic cardiomyopathy and thyrotoxicosis. 
Mitral stenosis and rheumatic heart disease have long been shown to 
increase the embolic frequency in patients with atrial fibrillation. In 
1951, Daley reported the presence of mitral valve disease in 97% and 
atrial fibrillation in 90% of his patients who experienced a systemic 
embolism (16). Szekely's series in 1964 identified mitral stenosis as a 
risk factor for embolization by reporting a seven-times higher incidence 
of embolization in patients with chronic rheumatic heart disease and 
atrial fibrillation, than patients with chronic rheumatic heart disease 
in normal sinus rhythm (14). An autopsy series by Aberg in 1969 
reported an embolic frequency of 53.5% in patients with atrial 
fibrillation and valvular (including mitral stenosis) or congenital 

heart disease. He also reported an embolic frequency of 54.3% in 
patients with atrial fibrillation and valvular disease combined with 
ischemic heart disease (5). In 1976, Henry et al also identified mitral 
stenosis as a risk factor for embolization but, reported a much lower 
frequency of embolization. Twenty-six percent (22/85) of his study 
population with mitral valve disease experienced a systemic embolic 
event (8). In 1977, Hinton’s autopsy series reported a 41% (29/70) 
embolic frequency in patients with atrial fibrillation and mitral valve 
disease (2). In 1978, results of a study by Neilson et al paralleled 
Henry's findings showing a 16.6% (37/234) embolic frequency among 
patients with mitral stenosis (4). The Framingham Study further 
supported these findings by reporting a seventeen fold increase in 
incidence of stroke among patients with chronic atrial fibrillation and 
rheumatic heart disease (8). Additionally, The Framingham Study 
reported that the presence of chronic atrial fibrillation alone placed 
patients at a five times greater risk for stroke than patients in normal 
sinus rhythm. 
Originally, ischemic heart disease was not considered to increase 
the risk of embolization in patients with atrial fibrillation. Early 
autopsy studies by Beer and Ghitman in 1961 reported only a 2% (1/50) 
incidence of embolization in patients with atrial fibrillation and 
ischemic heart disease (7). However, Aberg's study in 1969 contradicted 
this finding. Aberg reported a higher frequency of embolization in 
patients with atrial fibrillation and valvular disease and ischemic 
heart disease (5). In 1977, Hinton et al divided patients into groups 
having atrial fibrillation with mitral valve disease and atrial 
fibrillation with ischemic heart disease. Hinton reported a 35% 
(59/171) incidence of embolization in patients with atrial fibrillation 
and ischemic heart disease (2). With the separation of atrial 

fibrillation and ischemic heart disease from valvular disease, a risk of 
embolization comparable to that seen in mitral stenosis could be made. 
Consequently, recommendations for anticoagulation of this group were 
made. 
Although rare, hypertrophic cardiomyopathy has also been identified 
as a risk factor which increases the embolic frequency in patients with 
atrial fibrillation. Henry et al reported a 25% (8/32) embolic 
frequency among patients with atrial fibrillation and asymmetric septal 
hypertrophy. 
More recently, thyrotoxicosis has been associated with an increased 
embolic frequency among patients with atrial fibrillation. In 1980, 
Bar-Sela et al reported a 40% (12/30) embolic frequency in patients with 
thyrotoxicosis and atrial fibrillation (19). None of the patients with 
thyrotoxicosis without atrial fibrillation embolized (0/112). However, 
the authors note that the patients with atrial fibrillation had a higher 
prevalence of rheumatic and hypertensive heart disease (19), of which 
rheumatic heart disease is known to be an independent risk factor for 
embolization. 
In the majority of the studies discussed, no separation or 
comparison between chronic and paroxysmal atrial fibrillation was made. 
The Framingham Study included only patients with chronic atrial 
fibrillation as defined by the presence of atrial fibrillation on 
biennial examination (8). Daley et al report that the majority of 
embolic events in their study occur in chronic atrial fibrillation 
versus paroxysmal atrial fibrillation but the definition of chronic and 
paroxysmal atrial fibrillation is unclear (16). Henry et al report that 
91% of their embolic events occur in chronic atrial fibrillation which 
they define as atrial fibrillation present at the time of echocardiogram 
■ 
or if in sinus rhythm at the time of echocardiogram had a history of 
atrial fibrillation lasting more than 24 hours requiring cardioversion 
(3). Reports by Beer and Ghitman, Szekely, Aberg, Hinton et al, Neilson 
et al and Bar-Sela do not distinguish between the two types of atrial 
fibrillation. 
Despite other findings presented in the literature, it is still 
generally accepted that only the combination of atrial fibrillation and 
mitral stenosis poses a great enough risk of embolization to warrant 
long-term anticoagulation therapy and its complications. The present 
study sets out to identify whether left atrial chamber size can be used 
as a prognosticator of embolic risk in patients with atrial fibrillation 
without mitral stenosis. 
Systemic Embolism: 
An attempt was made to subdivide systemic emboli into definite, 
probable and possible according to laboratory information available to 
correlate the clinical diagnosis. Since the thrust of this study was to 
assess the influence of left atrial size on embolic frequency, the mean 
left atrial chamber sizes of the three subgroups were compared (P=NS). 
Therefore it was assumed for the remainder of this study, that all 
embolic events were correctly diagnosed regardless of ability to 
correlate the clinical diagnosis with laboratory findings. Thusfar, the 
distinction between embolic and thrombotic cerebral vascular accidents 
has been at best difficult, in all but autopsy reviews (17). Like Wolf 
et al in The Framingham Study, all strokes and transient ischemic 
attacks are considered embolic in this study (8). The overall frequency 
of systemic embolization in patients with atrial fibrillation without 
mitral stenosis was 29/176 (17%). Eighty-three percent were cerebral 

embolic events which is comparable to the previously reported frequency 
of cerebral emboli among patients with embolic events (5). 
Underlying Clinical Conditions: 
The presence of any underlying cardiac abnormality made a 
significant impact on embolic frequency in the study population. The 
presence of isolated non-mitral stenosis valvular disease or coronary 
heart disease did not significantly increase the embolic frequency in 
this study. These findings contrast reports by Aberg, Coulshed and 
Hinton of an increase embolic frequency in patients with valvular heart 
disease or congenital heart disease combined with atrial fibrillation. 
However, patients with the presence of any of the defined heart diseases 
in this study had an increased embolic frequency as compared to patients 
with no heart disease, 21/98 (21%) versus 8/78 (10%), respectively (P < 
.05). Multivariant analysis was not performed in this study. Therefore 
the effect of two or more underlying cardiac diseases on the embolic 
frequency could not be assessed. 
Chronic vs Paroxsysmal Atrial Fibrillation: 
This study also shows that chronic atrial fibrillation is 
associated with and increased frequency of embolization. Twenty-nine 
percent of patients with chronic atrial fibrillaiton embolized versus 
13% of patients with paroxysmal atrial fibrillation (P < 02). Henry et 
al reported that 91% (20/22) of their embolic events occurred in 
patients with chronic atrial fibrillation (3). Daley supports these 
findings with his report that the majority of embolic events occurred 
during chronic atrial fibrillation. The Framingham Study only included 
patients with chronic atrial fibrillation. Few studies have attempted 
■ 
18. 
to distinguish between paroxysmal and chronic atrial fibrillation. This 
may be due to the difficulty of distinguishing between the presence of 
paroxysmal or chronic atrial fibrillation without longterm cardiac 
monitoring. In this study chronic atrial fibrillation was defined by 
the absence of documented spontaneous sinus rhythm on two separate 
electrocardiograms one month or more apart. Patients who were 
chemically or electrically cardioverted were included in this group. In 
addition, it appears that not only the type of atrial fibrillation but 
the timing of the embolic event may have implications for 
recommendations of anticoagulation therapy. Other researchers have 
proposed that embolic events are most likely to occur in the first one 
month to six months of atrial fibrillation (3). The Framingham Study 
failed to identify such a vunerable period in their review. Although 
the present study reports that 28% of embolic events occurred within one 
month onset of atrial fibrillation, an additional 38% occur between 1 
month and 24 months. A total of 66% of the embolic events occurred 
within 2 years of onset of atrial fibrillation. Thus, when indicated, 
anticoagulation therapy while important at the onset of atrial 
fibrillation may be of benifit to patients found to be in atrial 
fibrillation of longer duration. 
Age: 
The incidence of embolization was found to increase among patients 
with increased age in this study population. The embolic group had a 
mean age of 75 years +_ 8 years compared to the nonembolic group mean of 
70 years _+ 13 years (P=.03). Coulshed and others have previously 
reported an increased incidence of systemic embolization in persons with 

increased age (15). 
As detailed earlier, the identification of subgroups of patients at 
risk for embolization with atrial fibrillation and other clinical 
entites have rarely resulted in the widespread use of anticoagulation 
therapy, except in the case of mitral stenosis. The results of this 
study also identify subgroups of patients at risk for embolization: 
patients with underlying organic heart disease, chronic atrial 
fibrillation and increased age. However, the most important finding in 
this study relates to left atrial chamber size and its ability to 
predict patients at risk for systemic embolization. 
Influence of Left Atrial Chamber Size: 
This series shows that a left atrial chamber size of A.Ocm or more 
is a very significant risk factor in patients having atrial fibrillation 
without mitral stenosis. The left atrial chamber measurements obtained 
in the usual fashion using 2-D and M-mode echocardiography revealed that 
25/116 (22%) patients with left atrial chamber size greater than or 
equal to A.Ocm experienced a systemic arterial embolic event. Four of 
sixty (7%) patients with left atrial chamber size less than A.Ocm 
embolized (P=.012A). These results show that a patient with atrial 
fibrillation without mitral stenosis with left atrial size greater than 
or equal to A.Ocm is at 3 times greater risk for embolization than a 
patient with left atrial size less than A.Ocm. Left atrial chamber size 
was determined on an average of 7 months (0 - A5 months) prior to 
embolization. Whether left atrial chamber size changes rapidly or 
significantly in the absence of mitral stenosis remains undetermined. 

20. 
A recently published abstract by D'Cruz et al reports that left 
atrial dimensions determined by echocardiography were found to be 
significantly larger in their embolic population. Ninety percent of the 
embolic group had enlarged left atrial size versus 20% of the nonembolic 
group. However, their study population was identified by the presence 
of a stroke. In their study population neither the onset of atrial 
fibrillation nor the type of atrial fibrillation was known. 
None of the embolic events occurred in patients on therapeutic 
anticoagulation demonstrated by prothrombin times in the therapeutic 
range (1.5 times control). Patients who experienced embolic events were 
not followed after their initial embolic event to assess the frequency 
of recurrent embolic episodes. The relative risk of embolization does 
not increase as left atrial size increases suggesting a threshold effect 
takes place near a chamber size of 4.0cm. The embolic group did not 
have many patients with left atrial chamber size greater than 5.0cm. 
Therefore, the number of patients did not lend itself to rigorous 
statistical analysis to challenge this possibility. 
One major bias in this study is the identification of patients with 
atrial fibrillation from a predominantly hospitalized population. 
Ninety-six percent of the patients in this study had the initial 
echocardiogram done as inpatients. This may have selected for patients 
with less ability to tolerate atrial fibrillation causing them to seek 
medical attention for symptomatology. Once these patients were 
identified in an inpatient setting, echocardiography could be easily 
obtained. Conversely, patients who are asymptomatic and find out they 
have atrial fibrillation on routine electrocardiogram may be less likely 
to have echocardiography recommended as part of their work-up. 

Conclusions: 
Among patients with atrial fibrillation without mitral stenosis the 
following conclusions are drawn: 
1. Patients with left atrial chamber size greater than or 
egual to A.Ocm are significantly more likely to 
embolize than patients with left atrial chamber size less 
than 4.0cm. 
2. Patients with underlying organic heart disease compared to 
those without underlying organic heart disease are more 
likely to embolize. 
3. Patients with chronic atrial fibrillation are more likely 
to embolize than those patients with paroxysmal atrial 
fibrillation. 
4. The risk of embolization is not confined to any discrete 
time period after the onset of atrial fibrillation. 
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The blackened portion of the bar graph shows the percent of 
patients with a given left atrial chamber size that embolize. No patients 
with left atrial chamber sizes less than 3.0cm or greater than 6.0cm 
experienced and embolic event. 
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Dear Mrs. Philopence: 
We are currently studying patients with an irregular heart beat who have 
undergone an echocardiogram during 1980-1983 at Yale-New Haven Hospital. At 
some point during this time period, your physician 'equested than an 
echocardiogram (a test to evaluate the heart's chambers and valves) be 
performed. In the next several weeks, a member of our research staff will be 
contacting you by telephone to ask you a few questions. These questions will 
pertain to your present state of health and medications you have been taking 
since you had an echocardiogram. The information gathered will not change 
your present therapeutic regimen in any way. The information gathered from 
you will be combined with information from other patients with irregular heart 
beats. Please be assured that all information will remain confidential and 
that you will not be identified by name in any reports of publications 
resulting from this study. 
We would appreciate your help in answering these questions which will 
only take approximately 10 minutes of your time and can be done on the 
telephone. Your participation is voluntary and you may refuse to participate 
or answer any particular questions without affecting future relationships with 
physicians at Yale-New Haven Medical Center. Please feel free to ask any 
questions during our conversation. 
Thank you in advance for your cooperation. 
Sincerely, 
/ 
i/. />,c ( 
Cynthia Hall, Medical Student 
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30. 
Atrial Fibrillation/Systemic Embolization Study Figure A 
I. Personal Background 
Name_Date of Birth_Sex_ 
Address___ 
Unit Number_Phone Number_Attending_ 
Date of Death_Cause_ 
II. Echo Data 
Date_Reason_ 
LA Size_ 
Other Echo Findings_ 
III. Other Medical Problems 
HTN CHF 
Tobacco RHD AoV_MV_Prosthesis_ 
EtOH Coronary Heart Disease 
Hyperthyroidism MI Date_ 
IV. Laboratory Tests and Interpretations 
Index ECG Date_ 
LA Enlargement Other Arrhythmias 
LVH MUGA Scan 
MI Index Chest X-Ray 
V. Medical Management of Arrhythmias 
DC Cardioversion Inpatient Anticoagulation 
Chemical Cardioversion Outpatient Anticoagulation 
Antiarrhythmics Beginning of Outpatient Anticoagulation 
type_ 
VI. Prothrombin Time Data 
PT less than 1.5 time control 
PT greater than or equal to 1.5-2 times control 

VII. Atrial Fibrillation History 
Date of ECG Therapy Drugs A. Fib. NSR Other 

32. 
VII. Symptoms and/or Documentation of Embolization 
CNS Date of Embolization_ 
CT Scan Findings_ 
Angiogram Findings_ 
Autopsy Findings_ 
Clinical Findings on Physical Examination_ 
presence of absence of carotid artery disease 





OTHER ABDOMINAL FINDINGS Date of Embolization_ 
Liver Infarction/Splenic Infarction/Kidney Infarction 
Liver/Spleen Scan Findings_ 
EXTREMITY 
Pain 
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This figure shows the distribution of embolic events according 
to duration of atrial fibrillation. Twenty-eight percent of the embolic 
events occur within one month of onset of atrial fibrillation, 17% between 
2 months and 12 months and 21% between 1 year and 2 years. This shows 
that the risk of embolization exist far longer than the 1-6 month period 









AGE Mean 75YRS+8YRS Mean 70YRS+13YRS 
SEX F 14(48%) 67(46%) 
M 15(52%) 80(54%) 
CHF 12(41%) 60(41%) 
HTN 18(62%) 63(43%) 
DIABETES 8(28%) 23(16%) 
THYROID 4(14%) 13(9%) 
CHD 17(59%) 61(42%) 
VALVE DX 7(24%) 11(8%) 
"OTHER"HD 4(14%) 18(12%) 
NO HD 18(62%) 118(80%) 
CHRONIC AF 12(41%) 29(20%) 
PAROXY AF 13(45%) 91(62%) 
UNDETERM AF 4(14%) 27(18%) 
DURATION Mean Mean 
OF AF 28mths (2days-108mths) 46mths (lwk-228mths) 
MTHS F/U Thiths (0-45mths) 35mths (0days-71mths) 
% EMBOLIZATION 
OF CHRONIC 12/41(29%) 0 
PAROXY 13/104(13%) 0 
UNDETERM 4/31(13%) 0 


























AGE - - - - - 71+13yrs 
SEX F 6(60%) 22(34%) 5(50%) 6(50%) 42(54%) 81(46%) 
M 4(40%) 43(66%) 5(50%) 7(54%) 36(46%) 95(54%) 
CHF 4(40%) 36(55%) 7(70%) 6(46%) 19(24%) 72(40%) 
HTN 6(60%) 33(50%) 5(50%) 6(46%) 31(40%) 81(46%) 
DIABETES 0 19(29%) 1(10%) 2(46%) 9(12%) 31(18%) 
HYPER- 
THYROID 1(10%) 8(12%) 0 0 8(10%) 17(10%) 
CHRONIC AF 5(50%) 19(29%) 2(20%) 7( 54%) 8(10%) 41(23%) 
PAROXY AF 5(30%) 37(57%) 4(40%) 5(39%) 55(71%) 104(59%) 
UNDETERM AF 2(20%) 9(14%) 4(40%) 1(8%) 15(19%) 31(18%) 
PERCENT 
EMBOLIZATION 
OF CHRONIC 2/5(40%) 4/19(21%) 0/2 3/7(43%) 3/8 (37%) 12/41(29%) 
PAROXY. 0/3 5/37(14%) 1/4(25%) 4/5(80%) 3/55(6%) 13/104(13% 
UNDETERM 0/2 1/9(11%) 1/4(25%) 0/1 2/15(13%) 4/31(13%) 
EMBOLIC 2(20%) 10(15%) 2(20%) 7(54%) 8(10% ) 29(17%) 
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